BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development
Go back to BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development| BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) | Delayed: 9.48 +0.34 (3.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.14 | 52 Week High | $10.98 | |||
| Open | $9.18 | 52 Week Low | $1.63 | |||
| Day High | $9.48 | P/E | N/A | |||
| Day Low | $9.10 | EPS | $-0.68 | |||
| Volume | 3,375,665 | |||||
